ORIGINAL RESEARCH



Physician Perceptions of Dose Escalation for Type 2 Diabetes Medications in the United States

Kristina S. Boye · Jessica B. Jordan · Raleigh Malik · Louis S. Matza 📵

Received: July 25, 2023 / Accepted: October 17, 2023 © The Author(s) 2023

ABSTRACT

Introduction: Medications used to treat type 2 diabetes (T2D) often require dose escalation to optimize effectiveness. Physician and patient perceptions of treatment characteristics of T2D medications have previously been examined, but little is known about perceptions of escalation to the optimal dose for each patient. This study examined physicians' perceptions of dose escalation for medications used to treat T2D.

Methods: Data on dose escalation and other factors influencing decision-making for treatment of T2D were collected via an online survey of endocrinologists and primary care physicians in the USA.

Results: The sample included 501 physicians (348 primary care physicians and 153

Prior Presentation: Parts of these study results were presented in a poster format at the American Diabetes Association 83rd Annual Scientific Sessions in San Diego, CA from 23–26 June 2023. The citation for this work is as follows: Boye K, Jordan J, Malik R, Cyr RA, Matza LS. 1054-P: A Physician Survey Focusing on Dose Escalation for Type 2 Diabetes Medications. Diabetes. 2023;72(Supplement1) https://doi.org/10.2337/db23-1054-P.

K. S. Boye \cdot R. Malik Eli Lilly and Company, Indianapolis, IN, USA

J. B. Jordan · L. S. Matza (⊠) Evidera, Bethesda, MD, USA e-mail: louis.matza@evidera.com endocrinologists). Dose escalation was not frequently considered by physicians as a primary factor keeping patients' from reaching treatment goals (mentioned as a factor by only 7.6% of the sample) or a barrier to prescribing T2D medication (16.2%). Factors more likely to keep patients from reaching treatment goals included an unhealthy diet (86.6%) and medication adherence (77.4%). The most common reasons that physicians reported for escalating dose levels were the need for better glycemic control (reported by 89.8% of the sample), ability to decrease the total number of medications by increasing the dose of one medication (39.9%), and the need for the patient to lose weight (39.3%). Data reported by primary care physicians and endocrinologists followed similar patterns.

Conclusions: Although common with T2D treatments, escalating the dose of T2D medication was not perceived by physicians to be a significant barrier to attaining treatment goals or prescribing medication. Multiple factors contribute to the decision to escalate the dose of T2D medication.


PLAIN LANGUAGE SUMMARY

In early phases of initiating medication treatment for a patient with type 2 diabetes (T2D), it is common for physicians to increase from a

△ Adis

Novo Nordisk Exhibit 2382

Published online: 18 November 2023



lower initial dose to a higher end dose to maximize treatment benefit. This process is known as dose escalation. The purpose of this study was to examine physicians' perceptions of dose escalation for medications used to treat T2D. An online survey was designed to identify reasons why physicians in the US may choose to escalate or not escalate a dose of medication for T2D. In addition, physicians were asked about factors that keep patients from reaching treatment goals to identify whether the requirement for dose escalation is perceived to be a common barrier to successful treatment. The sample included 501 physicians (348 primary care, 153 endocrinologists). Dose escalation was not frequently considered to be a primary factor keeping patients' from reaching treatment goals or a barrier to prescribing medication for T2D. Dose escalation decisions are complex, driven by a range of factors such as glycemic control medication tolerability, the patient's body mass index, treatment guidelines, comorbidities, characteristics of the patient's entire treatment regimen, and potential cardiovascular benefits.

Keywords: Type 2 diabetes; Dose escalation; Online survey; Primary care physician; Endocrinologist; Treatment goal; Prescribing barrier

Key Summary Points

Why carry out this study?

Because dose escalation is a common attribute of medications used to treat type 2 diabetes (T2D), it is important to understand its impact.

Little is known about physicians' perceptions of escalation to the optimal dose for each patient.

The purpose of this study was to conduct an online survey of endocrinologists and primary care physicians in the US to examine their perceptions of dose escalation for medications used to treat T2D.

What was learned from the study?

Results suggest that most physicians, including endocrinologists and primary care physicians, do not perceive dose escalation to be a significant challenge.

Dose escalation was not perceived to be a significant barrier to attaining treatment goals or prescribing medication.


Decisions to escalate a dose are complex, driven by a range of factors such as glycemic control, medication tolerability, the patient's body mass index, treatment guidelines, comorbidities, characteristics of the patient's entire treatment regimen, and potential cardiovascular benefits.

INTRODUCTION

A growing body of literature has focused on attributes of medications used to treat type 2 diabetes (T2D). Attributes examined in previous research include dose frequency, dose flexibility, glucose monitoring, adverse event profile, requirements for reconstituting the medication, and ease of preparing and using injection devices [1–14]. Attributes of the treatment process have been shown to affect medication adherence, which can have an impact on treatment outcomes [15–21]. In addition to the impact on patients, these medication attributes can also affect physicians' perceptions of treatments for T2D [22], which directly influence their choice of medications to prescribe for their patients.

Relatively limited research has examined the impact of dose escalation. Dose escalation is the process of increasing a fixed dose of medication from a lower initial dose to a higher end dose to optimize the medication's acceptability and efficacy [23]. Dose escalation is commonly required during the early phases of treatment with oral and injectable T2D therapies, such as metformin, liraglutide, tirzepatide, dulaglutide, and semaglutide [24–26]. Dose escalation is different from the individualized dose

△ Adis





adjustments in response to changes in a physiological parameter, often called "dose titration." For example, patients treated with multiple daily insulin injections regularly adjust their dose based on blood glucose levels [27].

Because dose escalation is a common attribute of medications used to treat T2D, it is important to understand its impact. In a previous study examining the patient perspective, dose escalation was perceived to be one of the least important characteristics of treatment for T2D [27]. However, physicians' perceptions of dose escalation remain largely unknown. Therefore, the purpose of this study was to examine physicians' perceptions of dose escalation for medications used to treat T2D. An online survey was designed to identify reasons why physicians may choose to escalate or not escalate a dose of medication for T2D. In addition, physicians were asked about factors that keep patients from reaching treatment goals to identify whether the requirement for dose escalation is perceived to be a common barrier to successful treatment.

METHODS

Study Design

In this cross-sectional study, physicians completed an online survey designed to assess their perceptions of dose escalation. Before completing the survey, physicians provided electronic consent and completed online screening questions to determine whether they were eligible to participate. The online survey was designed to take approximately 20-30 min to complete, and physicians who completed the survey were reimbursed. Participants provided informed consent before completing the survey. All procedures and materials were approved by a central institutional review board (22131-01A, Ethical and Independent Review Services), which was conducted in accordance with the Declaration of Helsinki. All surveys were completed from July to September 2022.

Participants

Participants were primary care physicians and endocrinologists licensed to practice medicine in the USA. To be eligible for this study, physicians were required to have been in medical practice for ≥ 1 year, treated an average of ≥ 10 patients with T2D per month, and prescribed injectable T2D medication (i.e., insulin or glucagon-like peptide-1 receptor agonists) for ≥ 3 patients in the 6 months prior to survey completion. Physicians were excluded if they were practicing medicine in a state where the Sunshine Act prohibits participation (i.e., Vermont and Massachusetts). An estimated sample size of approximately 400 to 500 physicians (approximately 70% primary care physicians, 30% endocrinologists) was targeted, roughly equally distributed across four US regions (Northeast, Midwest, South, and West). As the planned analyses were descriptive without a key statistical comparison, no power analysis was conducted when determining the sample size target. The sample size target was determined on the basis of similar surveys published in the past as well as practical implications.

Participants were recruited through a healthcare provider (HCP) panel built over a period of approximately 12 years by sourcing HCP contact data through direct physician outreach, conferences, LinkedIn outreach, ZoomInfo, institution websites, and PubMed. HCP status is confirmed at the time of opting into the panel by verifying their National Provider Identifier and implementing other quality control metrics. Panelist data are periodically cross-checked against online databases to ensure profiling remains accurate as time passes. The recruitment strategy for most of the study was to conduct a spam-resistant continual email campaign, sending study invitations to verified primary care physicians and endocrinologists in the HCP panel. However, for the initial soft launch of 15 physicians, a controlled email campaign was used to avoid over-recruitment and pause data collection as needed to identify any potential issues with the survey prior to full launch. For the full launch, the continual email campaign was initiated, usually sending emails every 2 days during the study period. The email

> △ Adis Novo Nordisk Exhibit 2382 Mvlan Pharms Inc. v. Novo Nordisk A/S



invitation briefly described the study and how much time it would take. A link was provided in the email invitation for the participant to click and be screened. If the screening questions determined that the participant was eligible, the participant would continue by completing the online physician survey. For this study, a total of > 30,000 email invitations were sent, and recruitment was discontinued when the sample size target was reached.

Online Physician Survey

To inform development of the survey, four clinical experts (three physicians with experience treating T2D and one clinical researcher who designs trials of medication for T2D) were interviewed about dose escalation. They were asked about factors they consider when deciding whether to escalate the dose of T2D medication, advantages and disadvantages of dose escalation, and the importance of dose escalation relative to other attributes of medication used to treat T2D. The content of the online survey was based on input provided during these qualitative interviews with physicians and a clinical researcher.

The survey began with instructions for completion. Respondents were instructed to answer the questions while thinking about "the broad range of antihyperglycemic medications for type 2 diabetes, including oral treatment like metformin, empagliflozin, and oral semaglutide; basal and meal-time insulin; and non-insulin injectable medications like liraglutide, injectable semaglutide, and dulaglutide." Then, a series of questions were administered to determine whether the physicians met study inclusion criteria. Physicians who met criteria continued by completing three additional background questions (see physician characteristics in Table 1). The next set of questions assessed the importance of dose escalation relative to other medication attributes. These items asked physicians to select from a list of medication attributes (presented in Tables 2 and 3) to indicate which attributes most commonly prevent patients from reaching treatment goals

and which attributes were most commonly perceived as a barrier to prescribing medication.

The final series of questions was designed to provide insight into physicians' decisions regarding dose escalation. For example, one question asked physicians to select from among a list of factors (presented in Table 4) they consider when deciding whether to escalate a dose of medication for T2D. Another item asked physicians to report the most common reasons for escalating a dose over the past 6 months, again by selecting from a list of potential reasons (presented in Table 5).

After each of the questions where physicians selected multiple responses from a list of options (i.e., Tables 2, 3, 4, 5), physicians were asked to rank their selections in order of importance. The exact wording of the key questions is presented in footnotes below the relevant tables.

After completing the draft survey, it was formatted for online completion and administered to the first 15 participants (i.e., 10 primary care physicians and 5 endocrinologists). Data collection was paused after these initial 15 participants so that results could be examined to ensure that the survey was functioning as intended. Results of the interim analysis led to two edits prior to continuing with data collection. First, the item assessing gender was moved to the screening section earlier in the survey so that gender could be considered as part of the screening criteria. Second, one question was deleted because it appeared to be potentially confusing. After making these two edits, the full data collection was allowed to proceed until the sample size target was met. Because no survey content was changed or added following the initial 15 completions, results from the pilot participants were included in the final dataset.

Statistical Methods

Descriptive statistics were used to summarize participants' responses and to characterize the sample in terms of sociodemographic characteristics and clinical background. For continuous variables, the mean, median, standard deviation, and range were calculated.

△ Adis






Table 1 Physician background information

Physician characteristics	Total sample (N = 501)	Primary care physicians (N = 348)	Endocrinologists (N = 153)	P value ^a
Years in medical practice (mean, SD)	18.7 (9.3)	18.8 (9.4)	18.4 (9.1)	0.606
Years managing or treating patients with T2D (mean, SD) $$	18.9 (9.3)	19.2 (9.4)	18.4 (9.2)	0.369
Practice setting description (n, %)				
Individual or small group practice	208 (41.5%)	161 (46.3%)	47 (30.7%)	0.004
Multi-specialty group practice	217 (43.3%)	135 (38.8%)	82 (53.6%)	
Hospital setting	57 (11.4%)	36 (10.3%)	21 (13.7%)	
Long-term care facility	6 (1.2%)	6 (1.7%)	0 (0.0%)	
Other	13 (2.6%)	10 (2.9%)	3 (2.0%)	
Gender (n, %)				
Male	320 (63.9%)	226 (64.9%)	94 (61.4%)	0.303
Female	176 (35.1%)	120 (34.5%)	56 (36.6%)	
Decline to respond	5 (1.0%)	2 (0.6%)	3 (2.0%)	
Region of practice in US (n, %)				
Northeast	130 (25.9%)	89 (25.6%)	41 (26.8%)	0.680
Midwest	117 (23.4%)	85 (24.4%)	32 (20.9%)	
South	139 (27.7%)	92 (26.4%)	47 (30.7%)	
West	115 (23.0%)	82 (23.6%)	33 (21.6%)	

SD standard deviation, T2D type 2 diabetes

Categorical variables are reported as frequencies and percentages. Analyses were conducted with SAS software version 9.4 (SAS Institute, Cary, NC).

RESULTS

Sample Characteristics

Of the 602 physicians who were screened, 501 (83.2%) met criteria for study inclusion, including 348 (57.8%) primary care physicians and 153 (25.4%) endocrinologists (Fig. 1). The

most common reasons for ineligibility were not being a primary care physician or endocrinologist (n = 47, 46.5%) and not seeing a sufficient number of patients with T2D per month (n = 13, 12.9%). The majority of physicians were male (n = 320, 63.9% of those who completed the survey), and most worked in either an individual or small group practice (n = 208, 41.5%) or a multi-specialty group practice (n = 217, 43.3%). Participants were roughly evenly distributed across the Northeast (n = 130, 25.9%), Midwest (n = 117, 23.4%), South (n = 139, 27.7%), and West (n = 115, 23.0%) regions of the US (Table 1).



△ Adis Novo Nordisk Exhibit 2382 Mylan Pharms, Inc. v. Novo Nordisk A/S

^aP values are for analyses comparing the two subgroups of participants in this table. The statistical tests were t tests for continuous variables and chi-square analyses for categorical variables

DOCKET

Explore Litigation Insights



Docket Alarm provides insights to develop a more informed litigation strategy and the peace of mind of knowing you're on top of things.

Real-Time Litigation Alerts



Keep your litigation team up-to-date with **real-time** alerts and advanced team management tools built for the enterprise, all while greatly reducing PACER spend.

Our comprehensive service means we can handle Federal, State, and Administrative courts across the country.

Advanced Docket Research



With over 230 million records, Docket Alarm's cloud-native docket research platform finds what other services can't. Coverage includes Federal, State, plus PTAB, TTAB, ITC and NLRB decisions, all in one place.

Identify arguments that have been successful in the past with full text, pinpoint searching. Link to case law cited within any court document via Fastcase.

Analytics At Your Fingertips



Learn what happened the last time a particular judge, opposing counsel or company faced cases similar to yours.

Advanced out-of-the-box PTAB and TTAB analytics are always at your fingertips.

API

Docket Alarm offers a powerful API (application programming interface) to developers that want to integrate case filings into their apps.

LAW FIRMS

Build custom dashboards for your attorneys and clients with live data direct from the court.

Automate many repetitive legal tasks like conflict checks, document management, and marketing.

FINANCIAL INSTITUTIONS

Litigation and bankruptcy checks for companies and debtors.

E-DISCOVERY AND LEGAL VENDORS

Sync your system to PACER to automate legal marketing.

